CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (25,828,095)	$ (24,270,521)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	794,414	419,630
Amortization of intangible assets	4,103,994	1,927,718
Amortization of deferred consulting fees	18,993	48,838
Amortization of deferred license fees	82,125	82,125
Amortization of deferred rent	(14,241)	(6,669)
Amortization of discount on related party convertible debt	3,667	0
Amortization of deferred license, royalty and subscription revenues	(280)	(124,882)
Amortization of prepaid rent in common stock	42,293	0
Net loss allocable to non-controlling interest	(5,151,013)	(2,583,581)
Stock-based compensation	3,320,773	2,375,354
Deferred income tax benefit	(5,174,977)	0
Gain/(loss) on sale or write-off of equipment	8,709	(5,120)
Write-off for uncollectible receivables	(16,356)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(86,124)	(66,310)
Grant receivable	65,859	932,925
Inventory	(74,873)	(5,816)
Prepaid expenses and other current assets	(113,635)	284,785
Other long term assets	0	(15,000)
Accounts payable and accrued liabilities	(1,544,520)	177,631
Accrued interest on convertible debt	1,143	0
Deferred revenues	(57,422)	(4,464)
Other long term liabilities	(124,442)	(48,322)
Net cash used in operating activities	(29,744,008)	(20,881,679)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(497,119)	(1,976,042)
Security deposit paid, net	(306,244)	(61,923)
Proceeds from the sale of equipment	4,000	30,900
Cash used in investing activities	(799,363)	(2,007,065)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of employee stock options	12,500	0
Proceeds from exercise of director stock options	207,000	0
Proceeds from issuance of common stock	0	23,810,421
Fees paid on sale of common stock	(297,932)	(748,072)
Proceeds from sale of common stock	14,724,107	0
Proceeds from sale of treasury stock and subsidiary warrants	13,582,209	1,819,500
Proceeds from sale of preferred stock	3,500,000	0
Proceeds from sale of common shares of subsidiary	468,000	255,502
Proceeds from issuance of related party convertible debt	466,690	0
Repayment of capital lease obligation	(12,537)	0
Net cash provided by financing activities	32,650,037	25,137,351
Effect of exchange rate changes on cash and cash equivalents	(185,909)	118,769
NET INCREASE IN CASH AND CASH EQUIVALENTS	1,920,757	2,367,376
CASH AND CASH EQUIVALENTS:
At beginning of the period	5,495,478	4,349,967
At end of the period	7,416,235	6,717,343
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	24,387	61
SUPPLEMENTAL SCHEDULE OF NON CASH FINANCING AND INVESTING ACTIVITIES:
Employee options exercised with common stock	972,700	0
Capital expenditure funded by capital lease borrowing	115,000	0
Common shares issued for consulting services	0	173,100
Common shares issued for rent	$ 0	$ 253,758